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Abstract: National drug policies address 
the health and social costs of drug use 
and the policing and security issues raised 
by drug production and trafficking. The 
strategic approach taken by governments 
needs to respond to problems linked to both 
established illicit drugs, such as heroin, 
cocaine and cannabis, and the rapidly 
evolving market for new psychoactive 
substances. This paper gives an overview of 
some recent developments in the tools most 
commonly used to manage national drug 
policies: strategies, coordination mechanisms 
and evaluations. It is based on an analysis of 
reports on national drug policies compiled 
by the European Monitoring Centre for 
Drugs and Drug Addiction’s (EMCDDA’s) 
Reitox focal points in the EMCDDA reporting 
countries (28 EU Member States, plus 
Turkey and Norway), consultation with 
experts and scientific literature. Among the 
issues identified, the report notes a gradual 
change; some national drug strategies have a 
broader scope, beyond illicit drugs, covering 
other substances and, to a lesser extent, 
other addictions. Twelve countries had a 
national illicit drug strategy document with 
a broad focus in 2016. An increased level of 
integration in planning of policy and provision 
marks what could be the start of a departure 
from the type of drug strategies that have 
been common until now. If it is, this will bring 
both new opportunities for wider public-
health-orientated cross-substance/addiction 
policies and challenges in effective resource 
assignment and action implementation. 
As more drug and addiction strategies are 
evaluated, new insights into this approach to 
strategic planning and its relative successes 
and future challenges will become more 
apparent.
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l Summary
This report provides an overview of developments in drug 
strategies in Europe, accompanied by an exploration of 
national coordination mechanisms and evaluations. In doing 
so, it identifies a trend, with an increasing number of national 
drug strategies taking a broader focus beyond illicit drugs 
and covering other substances and addictions. This analysis 
is based on reports from the European Monitoring Centre for 
Drugs and Drug Addiction’s (EMCDDA’s) Reitox national focal 
points, in addition to consultation with national experts and 
scientific literature.
l National strategies
National drug strategy documents set out a government’s 
position on drug policy issues. They define the problems and 
the response to them alongside varying mixtures of priorities, 
goals, objectives and actions. All of the EMCDDA’s 30 reporting 
countries (EU-28, plus Turkey and Norway) had active illicit 
drug strategy documents in 2016. Of these documents, 14 
were combined strategies and action plans, 13 countries had 
separate documents, with several sequential action plans 
being adopted, and 3 countries did not have an accompanying 
action plan.
Drug issues can be incorporated into higher-level strategies 
(e.g. a national health strategy), White Papers or addressed in 
multiple issue-specific papers concerned with different topics. 
Some drug strategies take the form of policy notes or letters, a 
declaration or a resolution.
Both the European Union (EU) Drug Strategy (2013-2020) 
and European countries’ individual strategies generally have 
similar core structures. This usually includes pillars (e.g. drug 
demand and drug supply reduction), cross-cutting themes 
(coordination; international cooperation; and information, 
research, monitoring and evaluation) and supported targeted 
actions. While the use of a pillar model that expresses the 
balanced approach between supply and demand reduction is 
well established, other aspects of these planning documents 
are starting to change.
Currently, more than a third of European countries include 
different combinations of other substances and behavioural 
addiction issues in their illicit drug strategies. This mainly 
involves objectives and measures related to other substances 
(alcohol, tobacco and medicines) and to a lesser extent 
behavioural addictions (e.g. gambling). Some traditional 
illicit drug strategies give minor consideration to alcohol and 
tobacco in their prevention pillars and sometimes in their 
treatment pillars. However, illicit drug strategies with a broader 
focus differ in having a more detailed consideration of other 
substances or addictions across the strategy’s pillars and in 
the specific measures addressing them.
Twelve countries have a national illicit drug strategy document 
with a broad focus. In addition, within the United Kingdom both 
the devolved administrations of Wales and Northern Ireland 
have broad strategy documents.
The majority of issues and measures in these broad documents 
are related to illicit drugs and there is variation in how other 
substances and addictions are considered. All the documents 
address alcohol, 10 consider tobacco, 8 cover medicines, (2 
focus on doping in sports (e.g. performance enhancing drugs)), 
and 7 look at addictive behaviours (e.g. gambling).
While a more integrated public health based view of addictions 
may be emerging, as evidenced by these broad strategy 
documents, it is still a developing trend. Over the last three 
decades, this trend towards the use of broader national 
strategies has developed from the existence of 2 at the end of 
the 1990s, rising to 4 during the 2000s and increasing annually 
after 2011 to 12 by the end of 2016.
l Coordination mechanisms
At the national level, drug policy is generally designed and 
endorsed by government ministers responsible for the area. 
Most European countries have a national drug coordinator. 
National strategic and operational coordination structures 
are attached to the ministry of health (or its equivalent) in 17 
of the countries. In the remainder, coordination structures 
are connected to the ministry of the interior, justice, family or 
social affairs and in some cases directly to the Prime Minister’s 
Office/Office of the Government (e.g. Czech Republic).
In Europe, coordination primarily takes place at the national 
and local levels. At both levels, a mix of strategic and 
operational management is undertaken. Most coordination 
systems have a national-level structure that manages 
the national drug strategy’s operational implementation, 
including facilitating communication between the many policy 
actors and the different stakeholders involved. Operational 
coordination typically involves monitoring and evaluating drug 
strategy implementation, preparing progress reviews and 
proposing the design for new strategies.
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l Evaluation
All countries report that their drug policies and strategies are 
evaluated through ongoing indicator monitoring and specific 
research projects. In some countries this is the only form of 
evaluation undertaken, while in others it is complemented by 
different types of evaluations of strategy documents.
The most commonly reported approaches to evaluation include 
a multi-criterion evaluation of a strategy and/or action plan at 
its mid- or end point; a review of the actions taken and/or the 
strategy’s context at its mid- or end point; an evaluation or audit 
of a specific policy or strategy aspect or area; and assessment 
through ongoing indicator monitoring, research projects, or 
regional or local strategy evaluation. In 2016 there were 10 
multi-criterion evaluations, 10 implementation progress reviews, 
and 4 issue specific evaluations were reported as having 
recently taken place, while 6 countries used other approaches 
involving a mix of indicator assessment and research projects.
l  Introduction — implementing and managing drug policies
This paper explores the state of play in Europe regarding drug 
strategies, coordination mechanisms and evaluations, which 
are the main tools used to implement and manage drug policy. 
The paper maps these three main policy areas, drawing on 
national data and examples where available.
Designing and implementing effective responses to the 
problems associated with illicit drug use is a complex task. 
The issues at stake range from the health and social costs 
of drug use to the policing and security challenges posed by 
drug production and trafficking. National drug policies need to 
respond to problems linked to both established illicit drugs, such 
as heroin, cocaine and cannabis, and the rapidly evolving market 
for new psychoactive substances (NPS), as well as polydrug use.
In the current climate, there are a series of important 
problems that policymakers are tasked with addressing 
through multi-level responses (EMCDDA, 2016; EMCDDA and 
Europol, 2016). Drug-related health problems, ranging from 
comorbidity to the spread of blood-borne viruses (human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV)) 
and drug-related overdoses, are serious problems in many 
countries. In terms of drug trafficking and supply, strategic 
responses are required to threats posed by organised crime 
groups. These gangs readily exploit both multiple trafficking 
routes and methods that threaten national security, public 
health and transport channels, placing pressure on resources 
at (air, sea and land) ports. Recent years have seen drug 
production becoming increasingly versatile; indoor cannabis 
cultivation and genetic engineering of plants, for example, have 
led to more potent products being produced and consumed 
within Europe close to local drug markets.
In drug policy, national drug strategy documents are widely 
used for planning purposes. These documents can contain an 
overarching vision for the area and a set of goals, principles 
and priorities that are translated into objectives and actions 
and are monitored and assessed through different indicators. 
Drug strategies developed through research and stakeholder 
consultation facilitate the expression of a shared statement 
of the problems being addressed and the resources required. 
These documents and the action plans that underpin them 
can help structure the work of multiple state and non-state 
stakeholders involved in designing and delivering drug policy.
The structural arrangements for coordinating the 
implementation of the actions in national drug strategies are 
also important tools in drug policy governance. As responses 
to drug-related problems tend to be implemented at different 
levels (individuals, families, communities) across a range 
of policy areas, the management of illicit drug problems by 
public administrations is referred to as a cross-cutting issue. It 
often involves the designation of one ministry, such as justice 
or health, as the lead on a policy area that incorporates the 
work of many other ministries and state services. Typically, a 
number of groups, committees, and task forces are established 
by governments to take forward strategic actions. It is here 
that the high-level goals and objectives of strategies meet the 
day-to-day issues of implementation. It is also within these 
structures that many local-level non-state policy actors have a 
space to interact directly with public administrations.
Evaluation is now a commonly employed tool in drug policy 
governance at the national level in European countries. 
Strategy evaluation is increasingly called for, as drug policy 
has developed as a specific area of public administration 
with financial and other resources assigned to it. National 
drug strategies and wider drug policies typically support the 
use of different responses in the areas of drug demand and 
drug supply reduction. The spectrum of measures used has 
increased over time. This includes initiatives that can be viewed 
in different national and local contexts in areas such as harm 
reduction and drug treatment, for example along a continuum 
from the conventional to the controversial (Hedrich, Pirona, 
and Wiessing, 2008). Much of this development has taken 
place in the era of new public management. This has brought 
about an increased focus on the use of research evidence in 
the design of policy and the scrutiny of how effective specific 
responses are and how efficiently resources are used. In this 
context, the evaluation of national drug strategies has become 
an important but complex issue.
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Data sources
This paper is based on an analysis of reports on national 
drug policy compiled by the European Monitoring Centre 
for Drugs and Drug Addiction’s (EMCDDA’s) Reitox 
focal points in the EMCDDA reporting countries (28 EU 
Member States, plus Turkey and Norway). It also draws on 
consultation with national experts. In addition, scientific 
literature on the core areas addressed was consulted. 
These data sources were used to develop a qualitative 
account of the state of play in the areas of national 
drug strategies, national coordination mechanisms and 
approaches to drug strategy evaluation. The resulting 
overview and analysis formed the basis for the current 
paper, which covers developments up to the end of 2016.
More information on the countries and their respective 
national drug situations can be found in the EMCDDA 
country drug reports.
A situational analysis of Europe’s drug problems and 
responses is presented in the EDR (European Drug 
Report) and the EU Drug Markets Report.
l  National drug strategies — broader scope and use
l From global to local strategies
The use of strategy documents to define problems and 
responses is well established in the area of illicit drugs. 
These are the documents in which both the overall direction 
and specific features of actions to address drug problems 
are generally set out. These strategies and plans are used at 
multiple levels and involve a wide range of policy actors (see 
Figure 1). For example, the United Nations’ (UN’s) ‘Political 
declaration and plan of action on international cooperation 
towards an integrated and balanced strategy to counter the 
world drug problem’ has a global focus (UNODC, 2009). Within 
Europe, the European Union’s (EU’s) ‘balanced approach’ to 
illicit drug problems is put forward in the EU Drug Strategy 
(2013-2020) and its Action Plan (2013-2016) (Council of the 
European Union, 2012; Council of the European Union, 2013), 
which represent the shared position of its Member States 
(MS), and similar strategies can be found in other regions 
(EMCDDA, 2014). These planning documents are key tools in 
the coordination of a European approach to drug issues and 
support the measures undertaken by EU MS. At the national 
level, such documents are used to set out the government’s 
position on how drug problems within the country as a whole 
should be addressed. Similarly, strategy documents are 
also used for this purpose in countries with devolved and 
autonomous regions. This is the case, for example, in the 
United Kingdom, within which Northern Ireland, Scotland 
and Wales are devolved administrations, and in Spain, which 
has 17 autonomous communities, as well as two cities with 
autonomous status. The implementation of national strategies 
at the local level is often supported through the use of 
strategies at the regional, city and local levels, as well as in 
issue-specific drug strategies (EMCDDA, 2015) (see Figure 1). 
Responses to drug problems are developed at and diffuse 
through these different levels of municipal, regional, national, 
supranational and international administration over time. 
Strategy documents have come to be the primary way in which 
these shared courses of action are set out, and endorsed and 
used as coordination tools by those involved in implementing 
drug policy.
All European countries use a national drug strategy as part 
of their approach to the management of drug problems and 
to set out specific measures being implemented and the 
general principles and priority courses of action. National 
drug strategies function to support actions that have often 
initially been developed from the levels below, typically the 
city, and merging these with the complexity of regional, 
national, supranational and international political and legal 
contexts (EMCDDA, 2015). The trend towards the use of 
strategic planning documents in the illicit drug policy area has 
developed significantly from the mid-1990s, when a third of 
the countries had one. At the turn of the century, two thirds 
of these countries had adopted one, with all having adopted 
one by 2016. One effect of this norm has been to give a more 
discernible shape to drug policies in terms of their overall 
direction.
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FIGURE 1
Drug strategies at different levels of administration
International Supranational National
Devolved administration Autonomous subnational region Regional 
City Local Issue-specific
l Strategy characteristics
A set of well-established features can be found in drug 
strategies irrespective of the level of governance at which they 
are used. This includes a definition of the problem and some 
principles about the approach to be taken, as well as varying 
mixtures of priorities, visions, goals, objectives and actions. 
The extent to which a strategy is current and responsive in 
the context of evolving drug problems largely depends on the 
period it spans and the level to which it has been developed.
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FIGURE 2
Cumulative adoption of national drug strategy documents in European countries (1983-2016)
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A drug strategy sits within a political and social context that 
is constantly changing. This is evident from the use of short-
term and issue-specific action plans by governments to keep 
the more long-term strategic documents that express the 
vision, principles and objectives of drug policy relevant and to 
address emerging situations. In some cases, multiple action 
plans are used to address different periods within the overall 
time frame of the strategy (e.g. Croatia) or to target different 
issues, such as specific substances (e.g. the Czech Republic). 
Drug strategies can also be updated or replaced to reflect the 
approach of a new government after it has taken office (e.g. the 
United Kingdom in 2010 and Hungary in 2013).
In 2016, a mix of approaches was evident in Europe, where 
14 countries had combined strategy/action plan documents 
(e.g. Ireland and Slovakia), 13 had separate documents, and 3 
countries did not have an accompanying action plan. Where 
separate documents are used, two or more sequential action 
plans are typically adopted to support implementation (e.g. 
Spain and Slovenia), mirroring the EU approach. Long-term 
policy documents can also accompany drug strategies and 
action plans, as is the case in both Portugal and Finland. It 
is in these documents that overarching principles have been 
defined that have then been carried forward through the 
objectives and actions of subsequent strategies.
l A European structure
Some countries incorporate drug issues into higher-level 
strategies (e.g. a national health strategy) while also 
accompanying them with targeted White Papers (reports that 
set out government policy) (e.g. Estonia and Norway) or use 
multiple issue-specific papers to address different topics (e.g. 
the Netherlands). In some countries, the strategy may be in 
the form of a policy note or letter (e.g. the Netherlands and 
Belgium (2001)) or a declaration (e.g. Belgium in (2010) or a 
resolution (Finland) that nonetheless is used as a defining and 
coordinating tool.
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FIGURE 3
The pillar model of drug strategies
Demand 
reduction
Supply 
reduction
Coordination
International cooperation
Information, research, monitoring and evaluation
Both the EU Drug Strategy (2013-2020) and the strategies 
of European countries follow similar core structures where 
the balanced approach to drug policy that places an equal 
emphasis on drug demand and supply reduction is expressed 
(see Figure 3). This involves a combination of pillars and cross-
cutting themes to set out issues of concern and group actions 
to address them. At the EU level the structure used includes 
the two pillars of drug demand and drug supply reduction 
alongside the three cross-cutting themes of coordination, 
international cooperation, and information, research, monitoring 
and evaluation (Council of the European Union, 2012).
The use of the pillar model can be regarded as a standard 
feature of the way in which national drug policies are expressed 
in European countries. Nonetheless, the exact combination 
of measures used to translate these common European drug 
policy principles into action varies from country to country. 
This is, in part, a reflection of the fact that European countries 
experience multiple and varied drug problems, with economic, 
historical, cultural and geographic factors playing a role. National 
governments use a range of policy approaches to respond to 
illicit drug problems. These include security, law enforcement and 
customs actions to reduce the supply of drugs and drug markets, 
and prevention, treatment, harm reduction and rehabilitation 
measures to address drug use and harms. While such measures 
and their inclusion within strategies are well established, other 
aspects of these planning documents are starting to change.
l Beyond illicit drugs
NPS are, by definition, not illicit drugs; however, most national 
drug strategies include NPS within the scope of objectives 
and actions aimed primarily at illicit drugs. This has been the 
case since the late 2000s, when strategy documents started 
to mention NPS (e.g. Ireland’s 2009-16 strategy), and is still 
common today. Consequently, while NPS are technically not 
illicit drugs until their status is changed through legislation, 
they constitute the largest group of substances, other than 
illicit drugs, that are specifically addressed in most strategies 
and action plans. As understandings of and responses to NPS 
are generally intertwined with measures against illicit drugs, in 
this paper the term ‘illicit drugs’ also encompasses NPS.
In addition to policies addressing illicit drugs, many European 
countries have policies on areas such as security, policing, 
tobacco, alcohol, prescription medicines, doping in sport 
and gambling. Various combinations of these issues are now 
being included in some illicit drug strategy documents with 
a broad focus (e.g. other substances and other addictions). 
This involves mainly alcohol and tobacco and to a lesser 
extent medicines, gambling and other behavioural addictions. 
Consequently, the scope, focus, implementation and resource 
requirements of national drug strategies are changing. The 
number of countries with a drug strategy with a broader focus 
is increasing and the state of play in 2016 is shown in Figure 4.
The move towards a broad approach is in some cases 
reflected in the introductions to strategy documents, with 
an acknowledgement of the need to take a more holistic 
approach. For example, in her introduction to the 2012 German 
drug and addiction policy, the Drug Commissioner of the 
Federal Government noted ‘In terms of numbers, the legal 
addictive substances such as tobacco, alcohol and medicinal 
products are the most prominent among the substances 
abused. New forms of addiction, such as gambling or internet 
addiction, are also coming to the fore’ (Drug Commissioner of 
the Federal Government, 2012, p. 3).
FIGURE 4
The focus of national drug strategy documents in 2016: 
illicit drugs or broader
Illicit drugs focus
Broader focus
NB: Strategies with broader focus may include, for example, licit drugs and
other addictions. While the United Kingdom has an illicit drug strategy, both
Wales and Northern Ireland have broad strategy documents which include
alcohol.
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FIGURE 5
Drug strategies with a broader focus (other substances and addictions) up to 2016
Country
Belgium
Czech Republic
Germany
France
Cyprus
Lithuania
Luxembourg
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United Kingdom — Northern Ireland
United Kingdom —  Wales
Norway
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Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
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Yes
Yes
Yes
Tobacco
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Yes
No
No
No
Medicines
Yes
No
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
No
No
Yes
Behavioural addictions
(e.g. gambling)
No
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
No
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No
No
Doping 
No
No
No
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No
No
No
No
No
No
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No
No
Yes
12 countries had a national illicit drug strategy document 
with a broad focus by the end of 2016. The United Kingdom’s 
national strategy document addresses only illicit drugs; 
however, the devolved administrations of Wales and Northern 
Ireland have broad strategy documents. When these two 
documents are included, the total number of broad illicit drug 
strategies increases to 14.
The majority of issues and measures in these broad documents 
are related to illicit drugs, and there is considerable variation 
in how other substances and addictions are considered. All 
14 documents address alcohol, 10 consider tobacco, 8 cover 
medicines, 7 look at addictive behaviours (e.g. gambling) and 3 
focus on doping in sports (e.g. performance enhancing drugs).
Within these more broadly focused documents, some 
strategies address different substances and issues at the level 
of goals and objectives, while in others they are addressed at 
the level of specific measures. It is important to note that all 
European countries have laws and other responses addressing 
the regulatory issues that impact upon other addictive 
substances and behaviours. What sets apart the group of 
countries in Figure 5 is that they are part of a trend towards 
combining statements regarding the strategic management of 
these areas in a single document. 
l Addressing addiction — the developing trend
While a more integrated public-health-based view of 
addictions may be emerging, as evidenced by these broad 
strategy documents, it is still an emerging trend. Over the last 
three decades, this trend towards the use of broader strategies 
has developed from 2 countries with them at the end of the 
1990s, rising to 4 countries with them during the 2000s and 
increasing annually since 2011 to the 12 countries and 14 
strategies identified here up to the end of 2016 (see Figure 6).
There are a number of factors that may lie behind these 
changes. In France, for example, the Roques report questioned 
the logic of handling addiction to illicit drugs and other 
substances separately and supported the widening of the 
scope of drug strategies (Roques, 1999). Since the start of 
this century, France has consistently adopted a broad drug 
and addiction approach in its strategy documents (Obradovic 
and Diaz Gomez, 2005; Beck, 2015). Portugal has taken an 
incremental approach to drug issues since its 1999 national 
drug strategy. It enacted a law in 2001 decriminalising the 
possession of drugs under certain quantity thresholds. Its 
current National Plan for Reducing Addictive Behaviours and 
Dependences (2013-2020) takes a wider view of addiction 
issues, including illicit drugs, alcohol, medicines and gambling. 
In the Czech Republic, there has been a call from different 
policy actors for alcohol to be included in the national drug 
strategy. This was one of the influences that led to the updating 
of the national drug strategy to include a focus on alcohol 
and gambling (Kissova, 2015). Together, these developments 
highlight the multiple contextual factors surrounding the 
different national-level changes towards the use of broader 
drug strategies.
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FIGURE 6
The trend towards drug strategies with a broader focus in European countries
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Broader focus
Illict drugs focus
The move towards the adoption of drug strategies with a focus 
beyond illicit drugs is a reflection, in part, of an increased focus 
on public health within drug and other policy areas at the 
national level. For example, Sweden’s Comprehensive Strategy 
for Alcohol, Narcotics, Doping and Tobacco (ANDT) situates 
its broad approach to addictive substances clearly within a 
wider public health context. A similar approach to defining 
the context of drug problems — spanning tobacco, alcohol, 
illicit drugs and medicines — is taken in Belgium in the 2001 
Federal Drug Policy Note and the 2010 Communal Declaration, 
and in Norway’s –2012 White Paper ‘A comprehensive drugs 
and alcohol policy’. Poland’s National Health Programme 
(2016-2020) addresses illicit drugs alongside other 
substances and addictions in a broad public health approach 
and takes the place of a stand-alone illicit drug strategy 
document. Luxembourg’s National Strategy and Action Plan 
on Drugs and Drug Addiction (2015-2019) includes illicit 
drugs and other substances alongside addictive behaviours. In 
the Czech Republic, a broad focus can also be seen from the 
way in which the national drug strategy (2010-2018) is being 
implemented through supporting action plans addressing illicit 
drugs, alcohol, tobacco and gambling.
l Addressing alcohol
The way in which alcohol is dealt with in recently published drug 
strategies with a broad focus provides an insight into the type 
of change taking place in these documents. For a long time, 
alcohol has been addressed to some extent in many national 
drug strategies. This frequently took the form of a few measures 
targeting alcohol as part of the prevention and treatment 
pillars of strategies. It rarely included much more than this or 
an extensive set of responses. One reason for this is that many 
countries also have a specific alcohol strategy or address it 
through detailed legislation or a wider public health strategy to an 
extent that negates the need for its inclusion in a drug strategy.
Current drug strategies with a broad focus mark a departure 
from this way of situating and addressing alcohol. These 
newer strategies tend to place alcohol as one of a number of 
substances and behaviours that receive a more equal focus 
across the different strategy pillars. We can now see, for 
example, sets of responses aimed at addressing the supply 
aspects of alcohol. In the current drug strategies with a broad 
focus in Germany, France, Cyprus and Portugal, the distribution, 
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marketing, sale and taxation of alcohol are considered, to 
different extents, alongside more established strategy actions 
around prevention and treatment (Drug Commissioner of the 
Federal Government, 2012; MILDT, 2013; Cyprus Anti-Drug 
Council, 2013; SICAD, 2013a). Within the United Kingdom, the 
drug strategies of both Wales and Northern Ireland include 
a substantial focus on alcohol issues (Welsh Assembly 
Government, 2008; Department of Health, Social Services and 
Public Safety, 2011).
The move towards the inclusion of alcohol in strategies in a more 
significant way is being driven by a mix of factors. The global 
burden of morbidity and mortality linked to alcohol consumption 
has also moved more clearly into focus. For example, the World 
Health Organization (WHO) notes that its WHO European 
Region has the world’s highest levels of both alcohol use and 
harms, with alcohol being the third leading cause of morbidity 
and premature mortality globally (WHO, 2012). The weight of 
research evidence into the harms caused by alcohol has been 
increasing, for example showing alcohol as a causal factor in the 
development of multiple forms of cancer (Connor, 2016).
Alcohol has progressively become established as a central 
problem in the drug consumption repertoires of illicit drug users 
within the context of polydrug use. Alcohol use also plays a role 
in the development of liver complications for injecting drug users 
infected with the hepatitis C virus (HCV). In addition, a body of 
research has grown on the harms caused to others by alcohol 
users’ consumption and behaviour (e.g. alcohol-related crime) 
and the impact it has on the quality of life of individuals, families 
and communities (WHO, 2012). Together, these and other issues 
that vary from country to country have contributed to increased 
debate around the use of alcohol and this has led, in some cases, 
to the substance’s inclusion in newly developed drug strategies.
l  National coordination mechanisms and drug strategies
National drug strategies help the different stakeholders 
involved in implementing drug policy develop a shared 
view of the issues at stake and an agreed course of action. 
Appropriately designed and resourced mechanisms enable 
a drug strategy to be translated into concrete action. Any 
coordination system needs to have a structure and access 
to resources and tools (data and analysis, decision-makers, 
finances, etc.) that are appropriately matched to the type of 
drug issues it is tasked with responding to. Systems need to 
be able to detect and address important issues in order to get 
the best use out of resources (Kenis, 2006). This section of the 
paper analyses the coordination arrangements that have been 
put in place by European countries monitored by the EMCDDA.
l Providing leadership
At the national level, drug policy is generally designed and 
endorsed by ministers with responsibility for the key areas 
in government. This activity is generally given a designated 
space within the broader arrangements that governments put 
in place to structure their action. In Bulgaria, for example, this 
type of coordination is carried out through the National Drugs 
Council, which is a body of Bulgaria’s Council of Ministers and 
is chaired by the Minister for Health.
The extent to which ministers are actively involved in drug 
policy changes and depends on many contextual factors. These 
include their relative weight compared with other issues in the 
constantly shifting mix of political priorities and the extent to 
which certain topics are being focused on by the media and 
civil society. The composition of national-level structures varies 
from country to country. In some cases, the prime minister 
can be the head of the structure (e.g. in Latvia). In other cases, 
the coordination structure can be presided over by a senior or 
junior minister who has been given the task of managing drug 
policy (e.g. in Ireland). The anchor ministry that this structure 
is attached to also varies from country to country, illustrating 
the cross-cutting nature of drug policy (see Figure 7). In 17 
European countries these structures are attached to the 
ministry of health (or its equivalent), while the remainder are 
connected to the ministry of the interior, justice, family or social 
affairs or, in some cases, directly to the Prime Minister’s Office/
Office of the Government (e.g. in the Czech Republic).
Most countries also have a dedicated national drug 
coordinator. If a senior or junior minister is not directly 
responsible for the drug strategy, a senior civil servant is often 
given this task. This is the case in Portugal, where the Director 
of the General-Directorate for Intervention on Addictive 
Behaviours and Dependencies (SICAD), who is attached to 
the Ministry of Health, is the National Coordinator for Drugs, 
Drug Addiction and Alcohol-Related Problems. Roles such as 
this are generally filled by senior civil servants familiar with 
the area. They are responsible for driving the strategy’s overall 
implementation and working with stakeholders at all levels. In 
many cases, the national drug coordinator chairs and manages 
either the ministerial or the operational coordination structures. 
For example, in Luxembourg, the Inter-ministerial Commission 
on Drugs is chaired by the National Drug Coordinator and is 
appointed by the Minister for Health.
l Strategic and operational coordination
One of the defining and challenging characteristics of drug 
policy coordination mechanisms is that they must be multi-
level in their design and operation. These structures integrate 
responsibility for the management of policy responses 
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spanning a variety of ministries, departments, agencies and 
other organisations. Much of this activity takes place around 
what has been termed the middle ground of coordination, that 
is, facilitating coordination ‘through the adoption of common 
goals, consensus building and inter-organisational mechanisms 
for working together’ (Hughes, Lodge and Ritter, 2010, p. 19).
FIGURE 7
National and local strategic and operational coordination structures
Country Lead ministry
National-level strategic and operational coordination 
structures
Local-level strategic and operational 
structures  
Belgium
Federal Public Service of 
Health, Food Chain Safety and 
Environment
Inter-Ministerial Conferences
General Drugs Policy Cell
This function is undertaken by national 
strucutres and local municipalities
Bulgaria Ministry of Health
National Drugs Council 
Narcotic Substances Section Municipal Drugs Councils 
Czech 
Republic Prime Minister's office 
Government Council for Drug Policy Coordination 
Government Council Secretariat Regional and local drug coordinators 
Denmark Ministry of Health Ministry of Health 
This function is undertaken by national 
strucutres and local municipalities
Germany Federal Ministry of Health
Office of the Federal Government Commissioner on 
Narcotic Drugs
The Länder Drug Commissioners and 
municipalities
Estonia
Ministry of Social Affairs
Ministry of the Interior
Government Committee on Drug Prevention 
Department of Public Health Health Coordination Committees
Ireland Department of Health
Oversight Forum on Drugs 
Drug Policy and Social Inclusion Unit 
Regional and Local Drug and Alcohol Task 
Forces
Greece Prime Minister's office 
Inter-ministerial Committee on the Drugs Action Plan
National Committee for the Coordination and Planning 
of Drugs Responses
This function is undertaken by national 
structures and local municipalities
Spain
Ministry of Health, Social 
Services and Equality
Government Delegation for the National Plan on Drugs 
Sector Conference on Drugs 
Inter-regional Commission on Drugs 
Spanish Council of Drug Addiction and other  
Addictions
Drug Plans of Autonomous Regions and 
Cities and some local municipalities
France Prime Minister's office 
Inter-ministerial Committee on Drugs
Inter-ministerial Mission for Combating Drugs and 
Addictive Behaviours (MILDECA)
Territorial representatives:
 § Chef de projet régional (at regional level)
 § Chef de projet départemental (at "County" 
level, that is, the lowest level of the State's 
Administration)
Croatia
Office for Combating Drug 
Abuse 
Commission for Combating Drug Abuse
Office for Combating Drug Abuse 
County Committees for Combating Drug 
Abuse
Italy Prime Minister's office Department for Anti-Drug Policies 
Regions, municipalities, and Local Health 
Units (ASL)
Cyprus
Cyprus Anti-Drugs Council 
(CAC)
Inter-Ministerial Drugs Committee 
Cyprus Anti-Drugs Council (CAC)
This function is undertaken by national 
structures and local municipalities
Latvia Prime Minister's office 
Drug Control and Drug Addiction Restriction 
Coordination Council
Council Secretariat 
This function is undertaken by national 
structures and local municipalities
Lithuania
Drug, Tobacco and Alcohol 
Control Department
Commission for Prevention of Drug Addiction and 
Alcohol Dependence 
Drug, Tobacco and Alcohol Control Department Municipality Drug Control Commission
Luxembourg Ministry of Health
Inter-ministerial Commission on Drugs 
Ministry of Justice and Ministry of Foreign Affairs
This function is undertaken by national 
structures and local municipalities
Hungary
Department for Social and 
Child Welfare
Inter-ministerial Coordination Committee on Drug 
Affairs (CICDA) 
National Drug Prevention Coordination Unit Coordination Forums on Drug Affairs (KEFs)
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Malta
Ministry for the Family and 
Social Solidarity
Advisory Board on Drugs and Addiction
National Co-ordinating Unit for Drugs and Alcohol
This function is undertaken by national 
structures and local municipalities
Netherlands
Ministry of Health, Welfare and 
Sport 
Ministry of Security and Justice 
Ministry of Foreign Affairs 
Ministry of Health, Welfare and Sport 
Ministry of Security and Justice 
Ministry of Foreign Affairs 
This function is undertaken by national 
structures and local municipalities
Austria Federal Ministry of Health
Federal Drug Coordination Office
Federal Drug Forum
Provincial Conference of Drug Coordinators, 
Provincial representatives 
Drug or Addiction Coordination Offices
Addiction Prevention Units
Poland Ministry of Health 
Council for Counteracting Drug Addiction 
National Bureau for Drug Prevention 
Provincial Drug Experts at the Marshall's 
Office
Local Borough (Gmina) Offices
Portugal Ministry of Health 
Council for Drugs, Drug Addiction and Alcohol-Related 
Problems 
Inter-ministerial Technical Commission
General-Directorate for Intervention on Addictive 
Behaviours and Dependencies (SICAD)
Regional Health Administrations (ARS) / 
Intervention Division in Addictive Behaviours 
and Dependencies (DICAD) 
Regional Secretaries of Welfare or Health in 
the Autonomous Regions
Romania Ministry of Internal Affairs National Anti-Drug Agency (NAA)
Drug Prevention, Evaluation and Counselling 
Centres
Slovenia
Ministry of Health
Ministry of the Interior
Commission on Narcotic Drugs of the Government of 
Slovenia
Health Promotion and Healthy Lifestyles Division 
This function is undertaken by national 
structures and local municipalities
Slovakia Ministry of Health 
Government Council for Drug Policy 
Department of Drug Strategy Coordination and 
Monitoring of Drugs
Regional coordinators for the prevention of 
criminality
Finland
Ministry of Social Affairs and 
Health 
National Drug Policy Coordination Group 
National Institute for Health and Welfare Provincial governments and municipalities
Sweden
Ministry of Health and Social 
Affairs Public Health Agency of Sweden County coordinators and municipalities
UK Home Office
Inter-Ministerial Group on Drugs, Home Office (UK)
Convention of Scottish Local Authorities (SCT) 
Substance Misuse National Partnership Board (WAL) 
New Strategic Direction Steering Group (NIR)
Local Authorities (UK) 
Alcohol and Drug Partnerships (SCT) 
Community Safety Partnerships (WAL) 
Drug and Alcohol Co-ordination Teams (NIR)
Turkey Ministry of Health 
High Council for the Fight Against Drugs 
Board for the Fight Against Drugs 
Technical Board for the Fight Against Drugs
Provincial and District Boards for the Fight 
Against Drugs
Norway
Ministry of Health and Care 
Services Directorate of Health 
Regional drug and alcohol competence 
centres, municipalities 
Two main levels of coordination can be identified across 
Europe: national and local coordination (1). The regional level is 
important in a few cases. At both of the first two levels, agencies 
are involved in delivering a mix of strategic and operational 
coordination to support drug strategy implementation. The 
actual agencies or mechanisms involved vary from country to 
country. Agencies responsible for strategic and operational 
coordination are typically tasked with monitoring and evaluating 
drug strategy implementation, preparing progress reviews 
and proposing the design for new strategies. In the Czech 
Republic, for example, the Government Council for Drug 
Policy Coordination’s Secretariat, which includes the National 
(1) These levels are used to provide a standardised and simple overview of 
coordination arrangements at the national level for monitoring purposes by 
the EMCDDA. A full overview of their use at the national level can be found 
online in the EMCDDA Country Drug Reports (available at http://www.emcdda.
europa.eu/countries).
Monitoring Centre for Drugs and Addictions, is tasked with day-
to-day strategy implementation and the coordination of the work 
being undertaken by different ministries. National coordination 
structures such as this are also tasked with managing 
programmes through which organisations delivering services in 
conjunction with the state receive funding, and with advising the 
ministerial level on emerging issues. This is the case in Ireland, 
for example, where the Department of Health’s Drug Policy Unit 
has a range of responsibilities that include the management of 
Regional and Local Drug and Alcohol Task Forces.
In principle, these agencies or bodies are generally expected 
to facilitate a mix of top-down and bottom-up coordination. 
This means that information, ideas and policy issues related 
to strategy implementation can travel from the government 
via the ministerial and operational levels to state and 
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non-state actors at the regional/local level. Simultaneously, 
these arrangements are also intended to assist non-state 
organisations that participate in them at different levels to 
communicate with the government and ministries.
Countries differ in the specific combination of structures they 
use and the relative levels of power that are assigned to them. 
For example, mechanisms can be based on state structures 
(federal or unitary) and the extent to which decision-making on 
policy and strategy implementation is retained at the national 
or federal level or devolved to the regional- or local-level 
structures. This difference is often visible in the perspective 
and scope of local-level drug strategies that are in line with, 
but have a more issue focused approach to certain drug 
and addiction problems (e.g. the Länder in Germany). The 
coordination systems of Austria (a federal state) and Lithuania 
(a unitary state) are shown in Figure 8. The presence of both 
levels of coordination — national and local, encompassing 
both regional- and municipal-level structures — reflects the 
decision-making and implementation cascade that is common 
throughout the national administrations of European countries.
FIGURE 8
Examples of national coordination mechanisms for drug strategies in federal and unitary states
(a) Austria (federal state)
Institutions and organisations
National administration (Federal Ministries*)
BMG BMJ BMI BMF BMUKK BMWF BMASK BMLVS BMVIT BMWFJ BMEIA
Provincial administration (Provincial Governments)
Burgenland Carinthia
Lower
Austria
Upper
Austria Salzburg Styria Tyrol Vorarlberg Vienna
DR AC DCDRACDRACACARACDRACARAC DR+DC
Addiction Prevention Units
Addiction
Prevention
Unit
Burgerland
Agency for
Addiction
Prevention
Carinthia
Addiction
Prevention
Unit
Lower 
Austria
Addiction
Prevention
Institute
Upper 
Austria
Akzente
Addiction
Prevention
Unit
Salzburg
VIVID
Addiction
Prevention
Unit
Styria
kontakt i co
Addiction
Prevention
Red Cross
Youth
Tyrol
SUPRO
Addiction
Prevention
Unit
Vorarlberg
ISP
Addiction
Prevention
Institute
Vienna
Specialised Centres
addiction and drug services providing treatment,
support, advice, reintegration and harm reduction
National networks*: ÖAKDA, ÖVDF, BAST, ...
Federal Drug
Coordination Oce
Federal Drug Forum
Provincial Conference
Working Group
for Addiction
Prevention
Addiction/Drug
Advisory Boards in
cities and communities
part of the provincial administration
external institution or expert
AC = Addiction Coordinator
AR = Addiction Representative
DC = Drug Coordinator
DR = Drug Representative
           (in Vienna: Drug Commissioner)
Coordinating Bodies
(b) Lithuania (unitary state)
Ministry of
Environment
Parliament of the Republic
of Lithuania
Drug and Alcohol Addiction
Prevention Commission
National Health Council
Government of the Republic
of Lithuania
Ministry of
Finance
Ministry of Social
Prevention and Labour
Ministry of
Culture
Ministry of
Transport
Ministry of
Agriculture
Ministry of
Health
Ministry of
Defence
Ministry of
the Interior
Ministry of
Economy
Ministry of
Foreign Aairs
Ministry of
Justice
Ministry of
Education and 
Science
Municipalities
Municipal Government Drug
Control Commissions
Drug, Tobacco
and Alcohol 
Department
Sources: Gesundheit Österreich GmbH, 2015a; Drug, Tobacco and Alcohol Control Department, 2014.
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l Broader implementing agencies
The trend towards the adoption of drug strategies with a 
broad focus in Europe, as identified in the previous section, 
brings with it new challenges. These include an increased 
complexity of implementation that is likely to have an impact 
on coordination structures and the delivery of strategic actions. 
For example, with an expanded number of substances, as 
well as illicit drugs and different behavioural addictions, 
to plan for, the number of stakeholders will grow and 
coordinating them will become a more demanding task. It is 
likely to involve active engagement with different systems of 
regulation encompassing alcohol, tobacco, medicines and new 
communication technologies. Nonetheless, this change may 
deliver more unified results in the context of a broader public 
health approach to addiction.
Several countries have already adopted coordination 
arrangements that integrate more diverse strategic functions 
across areas and substances. For example, in both the 
Czech Republic and Portugal, coordination structures were 
modified and given a wider scope following the adoption of 
drug strategies with a focus that included other substances 
and other addictions (SICAD, 2015a; National Monitoring 
Centre for Drugs and Addiction, 2015). Over the course of 
the last few decades, France has adopted several drug and 
addiction strategies, and its coordination structure has been 
revised more recently. The Inter-ministerial Mission for the 
Fight against Drugs and Drug Addiction (MILDT) was renamed 
the French Inter-ministerial Mission for Combating Drugs and 
Addictive Behaviours (MILDECA) in 2014. This is the result of 
a long process of widening its scope from illicit drugs towards 
alcohol, tobacco, pharmaceuticals and doping in 1999, and 
then to addictive behaviours (gambling and gaming) in 2013 
(MILDECA,2015). Responsibility for drug and addiction policy 
is shared in Germany, which has a federal structure, between 
the federal government, the Länder and municipalities, and 
other intermediate administrative structures where they exist 
(e.g. ‘districts’ in the Federal State of Bavaria) (Institute for 
Therapy Research, 2015a).
In some European countries, the scope of coordination 
structures extends beyond illicit drugs, irrespective of whether 
or not there is a drug strategy with a broad focus. For example, 
Malta has an illicit drug strategy, but its national coordination 
structures, the Advisory Board on Drugs and Addiction and 
the National Coordinating Unit for Drugs and Alcohol, have 
a wider focus (Malta National Focal Point, 2015). Similarly, 
in the Netherlands, the Ministry of Health is responsible 
for coordinating policy and responses on illicit drugs, other 
substances and other forms of addiction, but separate 
strategic planning documents are used for each area.
l National drug strategy evaluation
As with strategic planning tools in any policy area, drug 
strategies are periodically assessed. This helps governments 
track the progress of implementation, gauge the strategy’s 
continuing relevance and use the assessment in developing 
the strategy’s successor. Evaluation is a process designed 
to help establish the quality and value of actions and 
interventions. As the European Commission states, ‘Evaluation 
is a judgement of interventions according to their results, 
impacts and the needs they aim to satisfy. It is a systematic 
tool which provides a rigorous evidence base to inform 
decision making’ (European Commission, 2004, p. 9).
Drug problems are constantly evolving and countries usually 
have to address different drug problems through multiple 
responses simultaneously. This puts an extensive number of 
issues within the scope of drug policy, which makes evaluation 
both a key tool and a challenge to undertake. There are several 
Describing evaluation
As evaluation is complex and can take place at different 
levels, it is possible to locate different examples 
depending on the approach taken and the level at which 
it is applied. A range of parameters can potentially be 
involved. These include the following:
 § The level at which the evaluation takes place: whether 
it is assessing a policy, strategy, programme or project.
 § Who the commissioners are, such as state or non-
state entities (ministries or NGOs), and whether it is 
undertaken by an internal, external or mixed evaluation 
team. In practice, most ongoing indicator-based 
monitoring and implementation progress reviews are 
undertaken internally, while evaluation by means of 
specific research projects and multi-criterion evaluations 
is usually undertaken by a mixed internal/external team.
 § Timing, for example whether evaluation occurs before 
(ex ante), during (ex nunc) or after (ex post) the 
strategy being evaluated.
 § The specific scope, for example whether the evaluation 
focuses on a whole strategy or just some specific 
pillars, aspects, issues, measures or services that are 
delivered under the strategy.
 § The type of assessment criteria applied, for example 
relevance, implementation, outcome or a combination 
of these and other possible measures (coherency, 
efficiency, impact, effect or sustainability).
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levels at which evaluation can be used, ranging from the broad 
and strategic to the more defined and targeted. This span 
stretches from policies and strategies to programmes and 
projects. The scale and nature of some of the actions undertaken 
as part of a national drug strategy cover whole systems of care 
and the health of individuals, which makes devising evaluations 
that can directly prove the impact of a particular action hard to 
design. In general, it is far easier to show associations between 
different indicators and potential outcomes than it is to prove 
causation. Many factors influence health outcomes and it is 
difficult to identify a specific trigger of change.
l Evaluation in Europe
Following the trend towards increased use of drug strategies, 
the first published evaluations of national drug strategy 
documents emerged in 2003. By 2010, national strategy 
evaluation had become a relatively standard practice among 
European countries. Figure 9 shows the cumulative adoption 
of national drug strategies and the years in which final 
evaluations are reported as being published. Counting from 
this point, as opposed to the year when the mandate for 
undertaking an evaluation was given, provides an overview 
of completed assessments only, as there are cases where 
mandated evaluations were not undertaken or finished for 
various reasons. Currently, 25 countries have, in one way or 
another, evaluated a national drug strategy document. It is 
important to note, however, that in some countries evaluations 
of different projects and responses have long been undertaken 
and have functioned as assessments of measures outlined 
in strategies and action plans. This can be seen in France, 
which has a tradition of evaluating different projects such 
as, for example, l’Observatoire Français des Drogues et 
des Toxicomanies’s 1998 evaluation of Social Environment 
Committees in the area of prevention (Ballion, 1998).
l Approaches to evaluation
Drug policy has been noted as an area that is difficult to 
evaluate as a result of its complexity (EMCCDA, 2004). 
Evaluation is an activity that can involve many assessment 
methods. Pragmatism and political, time and financial 
pressures often lead to a modified approach to evaluation being 
used to assess national drug strategies. These evaluations 
defy neat categorisation based purely on scientific method 
(ideal type evaluations), as they typically incorporate elements 
of established best practices, but also fit the real-world 
circumstances in which national strategy assessment occurs. 
The EMCDDA uses a typology focused primarily on evaluation 
conducted within the framework of national governments’ 
strategic drug policy documents to monitor the assessments 
undertaken (see Figure 10). This categorisation incorporates 
both whole strategy and issue-focused evaluation, alongside 
ongoing monitoring and research aimed at supporting 
evaluation. In practice, there is often no neat divide between the 
types, and more than one may have been conducted.
FIGURE 9
Cumulative adoption of drug strategies and published evaluations in European countries (1983-2016)
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FIGURE 11
Overview of national drug strategy evaluations in 2016
Issue specic
Multi-criteria evaluation
Implementation progress review
Other approaches
Note: year beneath country name in map refers to 
year of publication
Key to categories used for 
describing evaluations
2016
2010
2016
2013
2014
2014
2009
2012
2012
2012
2012
2015
2016
2012
2013
2014
2014
2015
2016
2016
2009
2012
2013
2016
2016
Ongoing
Ongoing
Ongoing
Ongoing
Ongoing
Ireland
United Kingdom
Luxembourg
France
Greece
Cyprus
Belgium
Spain
Netherlands
Portugal
Malta
Turkey
Norway
Sweden
Finland
Estonia
Latvia
Lithuania
Germany
Poland
Italy
Denmark
Czech Republic
Slovakia
Hungary
Croatia
Austria Romania
Slovenia
Bulgaria
All the countries monitored by the EMCDDA report that 
they evaluate their drug policies and strategies by means of 
ongoing indicator monitoring and specific research projects. In 
some countries, this is the only form of evaluation undertaken, 
while in others it is complemented by different types of 
evaluations of strategy documents. In reality, most countries 
have both, but, to highlight points of departure between them, 
Figure 11 classifies countries according to recent strategy 
document evaluations where these have been reported; these 
countries are also undertaking ongoing indicator- and research 
based assessment. There were 10 multi-criterion evaluations, 
10 implementation progress reviews, and 4 issue specific 
evaluations reported in 2016 as having recently taken place, 
while 6 countries used other approaches like such as a mix of 
indicator assessment and research projects.
l Types of evaluation reported
It has become standard practice in many countries to 
undertake what can be termed a final evaluation of the national 
drug strategy. This type of evaluation can take the form of 
either a multi-criterion evaluation with a range of assessment 
questions or an implementation progress review of a drug 
FIGURE 10
Categories used for describing national evaluations
Multi-criteria evaluation A multi-criterion evaluation of a strategy and/or action plan at its mid- or end point
Implementation progress review A review of the actions taken and/or the strategy’s context at its mid- or end point
Issue-specific evaluation An evaluation or audit of a specific policy or strategy aspect or area
Other approaches Assessment via ongoing indicator monitoring, research projects, or regional or local strategy evaluation
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strategy and/or its action plan near its end date. Different 
methods are combined in various ways in these evaluations 
and all the countries that had undertaken one reported 
that a mixed-method approach was used. Frequently, final 
evaluations focus on the progress made in implementing 
the strategy and its relevance to the drug problems being 
faced. They usually do not focus on conclusions about the 
impact of the strategy on the drug situation, reflecting the 
aforementioned difficulties in demonstrating causation.
Drug strategies tend to be sequential, and evaluations 
generally take place a year or so prior to the strategy’s expiry 
date and are an important part of the process of developing a 
new one. Many of the evaluations reported in Figure 11 were 
completed prior to the development of a new national drugs 
strategy. This was the case, for example, with Luxembourg’s 
final evaluation of its National Strategy and Action Plan 
(2010-2014), which was used in the development of the 
National Strategy and Action Plan on Drugs and Addiction 
(2015-2019) (Trautmann and Braam, 2014; Origer, 2015). 
Similarly, in Portugal in 2012, an external final evaluation was 
undertaken of the country’s National Plan Against Drugs and 
Drug Addictions (2005-2012) (Gesaworld, 2013). At the same 
time, an internal evaluation of the last Action Plan (2009-2012) 
underpinning the strategy was completed (SICAD, 2013b). 
Both these evaluations were used in the process of developing 
a new post-2012 strategy. The recommendation was taken 
forward, resulting in the formulation of the National Plan for the 
Reduction of Addictive Behaviours and Dependencies (2013-
2020). This document expanded the scope of drug policy into 
the wider area of drugs and addiction (SICAD, 2015b).
A mid-term multi-criterion evaluation or implementation 
progress review allows countries to take stock of the progress 
being made in implementing their drug strategy midway 
through its lifetime. Typically, the scope of this type of 
assessment involves looking at the strategy as a whole and 
its implementation through the supporting action plan. For 
example, this was the case in Latvia in 2014, when a mid-term 
implementation progress review of the National Programme 
on Drug Control and Drug Addiction Restriction for 2011-
2017 was undertaken. This mixed-method evaluation was 
completed by an internal evaluation team within the Ministry 
of the Interior. It focused on the continued relevance and 
implementation of the action plan underpinning the strategy 
(Centre for Disease Prevention and Control, 2015). Other 
recent mid-term evaluations were reported by the Czech 
Republic, Spain and Poland.
Issue-specific evaluations or audits in some countries are 
focused on a drug policy in the wider sense or on specific 
issues. In the Netherlands, for example, a broad evaluation was 
undertaken of the country’s drug policy, spanning the work of 
many ministries. The scope of this evaluation was wider than 
the activities of the long-term Dutch policy document from 
1995 or the issue-specific strategies introduced subsequently 
(Van Laar and Van Ooyen-Houben, 2009). Evaluation, or 
assessments that approximate to it, can also take place in 
the form of reviews or audits focused on specific issues and 
strategy areas. The office of the auditor general in European 
countries can undertake different reviews that function as 
a type of evaluation or feed into evaluative judgements that 
can be made about a strategy, although an audit is not an 
evaluation per se. For example, in the United Kingdom, a report 
by the National Audit Office examined the drug strategy’s 
action on problem drug use, as well as work on drug-related 
offending, drug treatment and reintegration (National Audit 
Office, 2010). In Belgium, an evaluation of the country’s 
cannabis policy was undertaken (Plettinckx and Gremeaux, 
2015), while in Denmark different individual issue-specific 
evaluations focused on, among others, drug consumption 
rooms and have been used to assess drug policy (National 
Health Authority, 2015).
As noted above, other approaches towards the ongoing 
assessment of drug policy and strategy are used by some 
European countries where a national strategy document has 
not been evaluated. Such methods include the use of ongoing 
monitoring, the funding of research projects aligned with policy 
and strategy objectives, and the undertaking of evaluations of 
subnational-level (e.g. regional or local) strategy documents. 
Monitoring is a key step in the process of evaluation. In many 
countries, the Reitox national focal points play a key role 
in monitoring the implementation of strategies. Baseline 
and trend data enable meaningful observations to be made 
about how drug problems and responses have changed. 
All countries have active monitoring systems, and fund and 
participate in different research projects, and use this activity 
as an assessment tool for strategic actions. While this type 
of information is integral to evaluation efforts in all countries, 
it is the central tool in the ongoing approach to drug policy 
and strategy assessment in several countries. This includes 
Bulgaria, Greece and Lithuania, as well as Germany, where 
a range of projects are under continuous evaluation and 
epidemiological surveys are regularly undertaken (Institute for 
Therapy Research, 2015b; National Health Authority, 2015). 
In Austria, for example, different regional drug strategies 
have been evaluated. This was the case with Lower Austria’s 
Addiction Plan (2011-2015), which covers drugs and addictive 
behaviours. It was evaluated by an internal evaluation team as 
part of the process to develop a new strategy for 2016 onwards 
(Gesundheit Österreich GmbH, 2015b).
l Ongoing challenges
While the evaluation of national drug strategies is now 
an established part of the approach taken by countries to 
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implement drug policies, it remains a complex and challenging 
area. Assessing strategic actions allows governments to gain 
important insights into what has and what has not worked 
among the measures endorsed in drug strategies. Currently, 
national drug strategies are changing, with some having a 
wider scope than illicit drugs. At the same time, this trend is 
being slowly mirrored by the use of evaluations with a broader 
focus, as more countries have a strategy with a wider scope to 
evaluate (see Figure 12).
The blend of areas and issues addressed in drug strategies 
with a broad focus presents a more dynamic and multi-faceted 
set of strategic actions for evaluators to assess. This will bring 
changes to the style of evaluation that is adopted and could 
see a move towards more combined implementation reviews. 
All countries review their drug policies and strategies through 
the use of continuous indicator monitoring and research 
projects that relate to specific policy actions and interventions, 
while some undertake additional systematic evaluations of 
whole strategies and action plans. An approach based on 
monitoring and research allows a representative set of projects 
to be used to gain insight into a strategy. It will be interesting to 
follow whether or not this approach becomes more common 
in response to the challenges raised by a more diversified 
set of drug and addiction issues put forward in broader drug 
strategies.
FIGURE 12
Trend in number of countries with evaluations of 
strategies focusing on illicit drugs or strategies with a 
broad focus (2003-2016)
0
5
10
15
20
25
30
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
2
0
1
5
2
0
1
6
Broadly focused strategy evaluation
Illict drugs focused strategy evaluation
l  Conclusion — a widening strategic focus
National drug policies in Europe have for many years been 
managed and implemented through national drug strategy 
documents. Over time, a relatively standardised approach has 
developed around how actions are structured, coordinated and 
targeted, in many cases drawing on the model offered by the 
EU strategy and action plans. The need to coordinate the tasks 
that are spread between the supply and demand reduction 
areas and are managed through national and local structures 
lies at the core of the approach found in European countries, 
as does the use of evaluation to assess the actions being 
taken. This style of strategic planning in drug policy reflects the 
EU’s balanced approach to drug policy.
Drug issues continue to evolve, as the substances being 
consumed and the methods used to produce and traffic them 
change. Understandings of drug use and addiction have also 
shifted over time. There are a variety of theories of addiction 
that attempt to explain the reasons underlying why people 
use drugs. These theories can range from those drawing on 
neuroscience and disease models to those that incorporate 
social exclusion, geographic location and other factors that 
can have a bearing on lifestyle choices. Other theories or 
models attempt to give a unified account of addiction across 
substances and behaviours by looking at what is common and 
combining the plausible contributory elements from different 
theories with a more specific focus (EMCDDA, 2013). While 
there is no single view of addiction across countries’ drug 
strategies, what is considered to be legitimately within the 
scope of this policy area is changing.
Currently, an increased number of substances and behaviours 
are being discussed in relation to the effects of addiction. 
These range from alcohol, tobacco, prescription medicines, 
NPS and established illicit drugs to behavioural addictions 
(e.g. gambling) and the use of performance and image 
enhancing substances. At the same time, polydrug use is an 
increasing concern. These factors have contributed to a wider 
set of substances and behaviours being discussed in some 
national drug strategy documents. However, there is variation 
in how this trend towards strategies with a broader focus is 
manifested. In some countries, there has been a move towards 
accommodating broader concerns about addiction, while, 
in others, the focus remains predominantly on substances 
such as illicit drugs, alcohol, tobacco and medications. Most 
countries tend to address NPS in the context of, and within 
their responses to, illicit drugs, although NPS are technically 
not illicit drugs until their status is altered through legislation. 
This makes NPS the largest group of substances other than 
illicit drugs addressed in national drug strategies.
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At one level it can be asked whether or not the inclusion of 
other substances and addiction issues alongside illicit drugs 
within new, more holistic, strategies actually represents a 
significant change. Governments have always had responses 
to this range of problems, but have now started to more 
explicitly connect their strategic management. Not having a 
dedicated strategy document on a specific issue does not 
indicate that a government has no defined approach to an 
area. On the contrary, the shape of national policies can be 
discerned from legislation surrounding different issues or the 
use of other policy tools to deliver responses. For example, 
national approaches to tobacco, alcohol and gambling can 
be gleaned from legislation governing their regulation and 
the extent to which population-level public health or limited 
regulatory measures are included and/or funded (e.g. 
prevention measures and treatment places).
Individuals do not approach their own drug and addictive 
behaviours drug by drug, behaviour by behaviour (Dale 
Fontana, and Martinez, 2016). Acknowledging this and the 
connections between problems and responses to addiction, 
irrespective of how addiction manifests itself (in substance 
use or other behaviours), may give rise to an approach that 
combines previously separate policy statements and strategic 
plans into drug strategies with a broader focus.
An increased level of integration in planning of policy and 
provision marks what could be the start of a departure from 
the type of drug strategies that have been common until 
now. If it does, this will bring both new opportunities for wider 
public-health-orientated cross-substance/addiction policies 
and challenges in effective resource assignment and action 
implementation. Translating this type of change into action is 
bound to be a complex task given the different levels and areas 
of national administrations that must be coordinated on drug 
and addiction issues. As a strategy becomes broader in scope 
and more complex in implementation, devising indicators to 
monitor and evaluate it could also become more challenging. 
Strategies have, to date, retained the balanced approach to 
drug policy supported at the EU level with no major separation 
of drug supply reduction and drug demand reduction into 
components of wider security and public health strategies 
(EMCDDA, 2012). As more drug and addiction strategies are 
evaluated, new insights into this approach to strategic planning 
and its relative successes and future challenges will become 
more apparent.
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